Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]
Discontinued
Reference number: GID-TA10591
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer.
Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed.
As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes.